ValiRx plc (LON:VAL – Get Free Report) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as GBX 1.30 ($0.02) and last traded at GBX 1.40 ($0.02), with a volume of 105512 shares changing hands. The stock had previously closed at GBX 1.35 ($0.02).
ValiRx Trading Up 3.5 %
The company has a 50 day simple moving average of GBX 2.12 and a 200 day simple moving average of GBX 2.71. The company has a current ratio of 2.64, a quick ratio of 1.27 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of £1.85 million, a PE ratio of -67.50 and a beta of 0.59.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Featured Stories
- Five stocks we like better than ValiRx
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What is the Hang Seng index?
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- NYSE Stocks Give Investors a Variety of Quality Options
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
